Faculty Detail   
Name JOANNE T DOUGLAS
  
Campus Address CH19 201 Zip 2041
Phone  (205) 934-9261
E-mail  jdouglas@uab.edu
Other websites
    

Biographical Sketch 
Dr. Douglas is an Assistant Professor in the Department of Pathology, Division of Molecular and Cellular Pathology/Human Gene Therapy and is Associate Director of Education of the UAB Gene Therapy Center. She received a B.A. in Biochemistry from the University of Oxford and a Ph.D. in Molecular Microbiology from the University of Southampton, England.

Society Memberships
Organization Name Position Held Org Link
American Association for Cancer Research     
American Society for Microbiology     
American Society of Gene Therapy     
 

Research/Clinical Interest
Title
Gene Therapy
Description
The research in my laboratory is in the area of gene therapy. We are developing armed replicating adenoviruses for the treatment of cancer, particularly bone metastates of breast and prostate cancer. We are also developing targeted adenoviral vectors for novel therapeutic approaches to a range of diseases, particularly disorders of the muscle and bone.

Selected Publications 
Cody JJ and Douglas JT (2009). Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther advance online publication, 6 February 2009; doi:10.1038/cgt.2009.3.  19197323 
Ulasov IV, Tyler MA, Rivera AA, Nettlebeck DM, Douglas JT, Lesniak MS (2008). Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. J Med Virol 80: 1595-1603.

PMID:
 		 18649343  
Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT and Lesniak MS (2007). An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int J Oncol 31: 1177-1185.  17912445 
Douglas JT (2007). Adenoviral vectors for gene therapy. Mol Biotechnol 36: 71-80.  17827541 
Kim M, Bodenstine TM, Sumerel LA, Rivera AA, Baker AH and Douglas JT (2006). Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo. Cancer Biol Ther 5: 1647-1653.  17106248 
Kim M, Sumerel LA, Belousova N, Lyons GR, Carey DE, Krasnykh V and Douglas JT (2003). The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br J Cancer 88: 1411-1416.  12778071 
Douglas JT (2003). Cancer gene therapy. Technol Cancer Res Treat 2: 51-63.  12625754 
Barnett BG, Tillman BW, Curiel DT and Douglas JT (2002). Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol Ther 6: 377-385.  12231174 
Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT and Douglas JT (2002). The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 38: 1917-1926.  12204675 
Barnett BG, Crews CJ and Douglas JT (2002). Targeted adenoviral vectors. Biochim Biophys Acta 1575: 1-14.  12020813 
Douglas JT, Kim M, Sumerel LA, Carey DE and Curiel DT (2001). Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res 61: 813-817.  11221860 
Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh V and Curiel DT (1999). A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 17: 470-475.  10331807 
Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M and Curiel DT (1996). Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14: 1574-1578.  9634824 
 

Keywords
Cancer, Gene Therapy